Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Schellhammer

Showing results (291-300 of 326) with videos related to

Pageof 33
Sort By:
Cancer Research|January 1, 1986
Human prostate tissue antigens defined by murine monoclonal antibodiesJ J Starling, S M Sieg, M L Beckett, et al.
International Journal of Cancer|October 21, 2003
Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapyKenneth D Somers, Roy R Brown, Daniel A Holterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapyRichard P Ciavarra, Daniel A Holterman, Roy R Brown, et al.
International Journal of Oncology|September 21, 2000
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapyL S Incognito, L H Cazares, P F Schellhammer, et al.
Urologic Oncology|January 14, 2011
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future directionH Akaza, K H Kurth, R Williams, et al.
Urology|December 1, 1996
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasiaG M Marley, M C Miller, M W Kattan, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
The Journal of Urology|August 1, 1995
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancerM F Sarosdy, R W deVere White, M S Soloway, et al.
Urologic Oncology|November 23, 2005
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group StudyMichael F Sarosdy, Catherine M Tangen, Geoffrey R Weiss, et al.
The Journal of Urology|March 23, 2010
Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancerJohn B Malcolm, Michael D Fabrizio, Bethany B Barone, et al.
Pageof 33

Showing results (291-300 of 326) with videos related to

Sort By:
Pageof 33
Cancer Research|January 1, 1986
Human prostate tissue antigens defined by murine monoclonal antibodiesJ J Starling, S M Sieg, M L Beckett, et al.
International Journal of Cancer|October 21, 2003
Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapyKenneth D Somers, Roy R Brown, Daniel A Holterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapyRichard P Ciavarra, Daniel A Holterman, Roy R Brown, et al.
International Journal of Oncology|September 21, 2000
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapyL S Incognito, L H Cazares, P F Schellhammer, et al.
Urologic Oncology|January 14, 2011
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future directionH Akaza, K H Kurth, R Williams, et al.
Urology|December 1, 1996
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasiaG M Marley, M C Miller, M W Kattan, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
The Journal of Urology|August 1, 1995
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancerM F Sarosdy, R W deVere White, M S Soloway, et al.
Urologic Oncology|November 23, 2005
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group StudyMichael F Sarosdy, Catherine M Tangen, Geoffrey R Weiss, et al.
The Journal of Urology|March 23, 2010
Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancerJohn B Malcolm, Michael D Fabrizio, Bethany B Barone, et al.
Pageof 33